Cytogenetic Damage Induced by Radioiodine Therapy: A Follow-Up Case Study
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24065128 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Igor K Khvostunov und 9 weiteren Autor:innen. Beteiligte Einrichtung: A.F. Tsyb Medical Radiological Research Center (MRRC)-Branch of the National Medical Research Radiological Center of the Ministry of Health of the Ru…. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The risk of toxicity attributable to radioiodine therapy (RIT) remains a subject of ongoing research, with a whole-body dose of 2 Gy proposed as a safe limit. This article evaluates the RIT-induced cytogenetic damage in two rare differentiated thyroid cancer (DTC) cases, including the first follow-up study of a pediatric DTC patient. Chromosome damage in the patient’s peripheral blood lymphocytes (PBL) was examined using conventional metaphase assay, painting of chromosomes 2, 4, and 12 (FISH), and multiplex fluorescence in situ hybridization (mFISH). Patient 1 (female, 1.6 y.o.) received four RIT courses over 1.1 years. Patient 2 (female, 49 y.o.) received 12 courses over 6.4 years, the last two of which were examined. Blood samples were collected before and 3–4 days after the treatment. Chromosome aberrations (CA) analyzed by conventional and FISH methods were converted to a whole-body dose accounting for the dose rate effect. The mFISH method showed an increase in total aberrant cell frequency following each RIT course, while cells carrying unstable aberrations predominated in the yield. The proportion of cells containing stable CA associated with long-term cytogenetic risk remained mostly unchanged during follow-up for both patients. A one-time administration of RIT was safe, as the threshold of 2 Gy for the whole-body dose was not exceeded. The risk of side effects projected from RIT-attributable cytogenetic damage was low, suggesting a good long-term prognosis. In rare cases, such as the ones reviewed in this study, individual planning based on cytogenetic biodosimetry is strongly recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- A.F. Tsyb Medical Radiological Research Center (MRRC)-Branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, 4 Koroliova St., 249036 Obninsk, Russia.
- Joint Institute for Nuclear Research (JINR), 6 Joliot-Curie St., 141980 Dubna, Russia.
- Federal State Budgetary Institution, National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, 2 Botkinskiy Proezd, 125284 Moscow, Russia.
- Federal State Autonomous Educational Institution of Higher Professional Education, Department of Oncology and Radiology Named after N.P. Kharchenko, Medical Institute, Peoples' Friendship University of Russia, 117198 Mo…
ORCID-Profile: Elena Nasonova
Zitieren
APA
Khvostunov, I. K., Nasonova, E., Krylov, V., Rodichev, A., Kochetova, T., Shepel, N., Korovchuk, O., Kutsalo, P., Shegai, P., & Kaprin, A. (2023). Cytogenetic Damage Induced by Radioiodine Therapy: A Follow-Up Case Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24065128
Vancouver
Khvostunov IK, Nasonova E, Krylov V, Rodichev A, Kochetova T, Shepel N, et al. Cytogenetic Damage Induced by Radioiodine Therapy: A Follow-Up Case Study. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24065128
BibTeX
@article{Khvostunov2023,
author = {Khvostunov, Igor K and Nasonova, Elena and Krylov, Valeriy and Rodichev, Andrei and Kochetova, Tatiana and Shepel, Natalia and Korovchuk, Olga and Kutsalo, Polina and Shegai, Petr and Kaprin, Andrei},
title = {Cytogenetic Damage Induced by Radioiodine Therapy: A Follow-Up Case Study},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24065128}
}
EUVIMED